# US 2021/0277403 A1 · Methods and compositions for targeting pd-l1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277403 A1
- Document ID: US20210277403A1
- Status: Published application
- Kind: A1
- Application number: 17/249,337
- Filed: 2021-02-26
- Published: 2021-09-09
- Earliest claimed: 2020-02-28
- Assignees: Aligos Therapeutics, Inc.
- Applicants: Aligos Therapeutics, Inc.
- Inventors: Leonid Beigelman; Megan Elizabeth Fitzgerald; Saul Martinez Montero; Aneerban Bhattacharya
- Web page: https://patentgrep.com/patent/US20210277403A1

## CPC

- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/343: having patterns, e.g. ==--==--==--
- C12N 2310/351: Conjugate
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to small interfering RNA (siRNA) molecules directed to mRNA transcripts of CD274 to cause downregulation of programmed death-ligand 1 (PD-L1) expression in humans. The siRNA can be constructed of unmodified nucleotides or modified nucleotides that exhibit modified sugars, nucleobases, linkages, or covalently bound targeting moieties. Also disclosed herein are pharmaceutical compositions of siRNAs and uses of or methods of using the siRNAs for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

## Claims

### Claim 1

A small interfering RNA (siRNA) that targets human CD274 mRNA, comprising a sense strand and an antisense strand, wherein the antisense strand comprises 18 to 21 nucleotides selected from the group consisting of unmodified nucleotides and modified nucleosides,
wherein each modified nucleoside contains a modified sugar, contains a modified nucleobase or is abasic, or both contains a modified sugar and contains a modified nucleobase or is abasic;
wherein each linkage between the nucleosides is a phosphorothioate, phosphodiester, phosphoramidate, thiophosphoramidate, methylphosphate, methylphosphonate, phosphonoacetate, amide, boranophosphate, or any combination thereof; and
wherein the siRNA is at least 85% complementary to a fragment of human CD274 mRNA.

### Claim 2 (depends on 1)

The siRNA of claim 1, wherein the siRNA comprises zero, one, or two mismatches to the fragment of human CD274 mRNA.

### Claim 3 (depends on 2)

The siRNA of claim 2, wherein the mismatches occur at any one or more of positions 1 or 9 through m, wherein m is the total number of nucleotides in the antisense strand.

### Claim 4 (depends on 2)

The siRNA of claim 2, wherein the mismatches do not occur at a seed region of the siRNA.

### Claim 5 (depends on 4)

The siRNA of claim 4, wherein the seed region is at positions 2-8.

### Claim 6 (depends on 1)

The siRNA of claim 1, wherein the siRNA has a sequence as set forth in any one of SEQ ID NOs: 2-380.

### Claim 7 (depends on 1)

The siRNA of claim 1, wherein the siRNA has 18 nucleotides.

### Claim 8 (depends on 1)

The siRNA of claim 1, wherein the siRNA has 19 nucleotides.

### Claim 9 (depends on 1)

The siRNA of claim 1, wherein the siRNA has 20 nucleotides.

### Claim 10 (depends on 1)

The siRNA of claim 1, wherein the siRNA has 21 nucleotides.

### Claim 11 (depends on 1)

The siRNA of claim 1, further comprising a 2-nucleotide overhang.

### Claim 12 (depends on 11)

The siRNA of claim 11, wherein the 2-nucleotide overhang is non-complementary to the CD274 mRNA.

### Claim 13 (depends on 1)

The siRNA of claim 1, wherein the modified sugar is selected from the group consisting of 2′-OMe, 2′-F, 2′-MOE, 2′-araF, 2′-araOH, 2′-OEt, 2′-O-alkyl, LNA, scpBNA, AmNA, cEt, ENA, and GNA.

### Claim 14 (depends on 1)

The siRNA of claim 1, wherein the antisense strand comprises a 5′-phosphate group or a 5′-phosphate mimic.

### Claim 15 (depends on 14)

The siRNA of claim 14, wherein the 5′-phosphate mimic is a 5′-vinylphosponate.

### Claim 16 (depends on 1)

The siRNA of claim 1, further comprising a targeting moiety.

### Claim 17 (depends on 16)

The siRNA of claim 16, wherein the targeting moiety is conjugated to the siRNA at the 5′ end, 3′ end, or both.

### Claim 18 (depends on 16)

The siRNA of claim 16, wherein the targeting moiety is a fatty acid, GalNAc, folic acid, cholesterol, tocopherol, or palmitate.

### Claim 19 (depends on 1)

The siRNA of claim 1, wherein the modified nucleoside is selected from the group consisting of:
wherein R1 is hydrogen or C1-7 alkyl.

### Claim 20 (depends on 19)

The siRNA of claim 19, wherein the Base is selected from the group consisting of adenine, guanine, cytosine, 5-methyl cytosine, thymine, and uracil.

### Claim 21 (depends on 1)

A pharmaceutical composition comprising an effective amount of the siRNA according to claim 1 and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 1)

A method for treating hepatitis B in a subject comprising administering to the subject in need thereof an effective amount of an siRNA of claim 1.

### Claim 27 (depends on 1)

A method for treating hepatocellular carcinoma (HCC) in a subject comprising administering to the subject in need thereof an effective amount of an siRNA of claim 1.

### Claim 28 (depends on 27)

The method of claim 27, further comprising administering surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, hormonal therapy, or antiviral therapy.
